

Recombinant Therapeutic Antibodies and Proteins Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/RD3190E1EB02EN.html>

Date: April 2022

Pages: 63

Price: US\$ 3,250.00 (Single User License)

ID: RD3190E1EB02EN

Abstracts

Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.

This report contains market size and forecasts of Recombinant Therapeutic Antibodies and Proteins in Global, including the following market information:

Global Recombinant Therapeutic Antibodies and Proteins Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Recombinant Therapeutic Antibodies and Proteins market was valued at 92080 million in 2021 and is projected to reach US\$ 144220 million by 2028, at a CAGR of 6.6% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Plasma Protein Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Recombinant Therapeutic Antibodies and Proteins include Abbott, Amgen, Biogen, Eli Lilly, Roche, Johnson and Johnson, Merck, Novo Nordisk and Pfizer and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Recombinant Therapeutic Antibodies and Proteins companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Recombinant Therapeutic Antibodies and Proteins Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Recombinant Therapeutic Antibodies and Proteins Market Segment Percentages, by Type, 2021 (%)

Plasma Protein

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

Global Recombinant Therapeutic Antibodies and Proteins Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Recombinant Therapeutic Antibodies and Proteins Market Segment Percentages, by Application, 2021 (%)

- Oncology
- Hematology
- Immunology
- Endocrinology
- Infectious Disease
- Cardiovascular Disease
- Others

Global Recombinant Therapeutic Antibodies and Proteins Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Recombinant Therapeutic Antibodies and Proteins Market Segment Percentages, By Region and Country, 2021 (%)

- North America
 - US
 - Canada
 - Mexico
- Europe
 - Germany
 - France
 - U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Recombinant Therapeutic Antibodies and Proteins revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Recombinant Therapeutic Antibodies and Proteins revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Abbott

Amgen

Biogen

Eli Lilly

Roche

Johnson and Johnson

Merck

Novo Nordisk

Pfizer

Sanofi

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Recombinant Therapeutic Antibodies and Proteins Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Recombinant Therapeutic Antibodies and Proteins Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL RECOMBINANT THERAPEUTIC ANTIBODIES AND PROTEINS OVERALL MARKET SIZE

- 2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size: 2021 VS 2028
- 2.2 Global Recombinant Therapeutic Antibodies and Proteins Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Recombinant Therapeutic Antibodies and Proteins Players in Global Market
- 3.2 Top Global Recombinant Therapeutic Antibodies and Proteins Companies Ranked by Revenue
- 3.3 Global Recombinant Therapeutic Antibodies and Proteins Revenue by Companies
- 3.4 Top 3 and Top 5 Recombinant Therapeutic Antibodies and Proteins Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Recombinant Therapeutic Antibodies and Proteins Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Recombinant Therapeutic Antibodies and Proteins Players in Global Market

3.6.1 List of Global Tier 1 Recombinant Therapeutic Antibodies and Proteins Companies

3.6.2 List of Global Tier 2 and Tier 3 Recombinant Therapeutic Antibodies and Proteins Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Recombinant Therapeutic Antibodies and Proteins Market Size Markets, 2021 & 2028

4.1.2 Plasma Protein

4.1.3 Fusion Proteins

4.1.4 Monoclonal Antibodies

4.1.5 Hormones

4.1.6 Enzyme

4.1.7 Coagulation Factors

4.1.8 Others

4.2 By Type - Global Recombinant Therapeutic Antibodies and Proteins Revenue & Forecasts

4.2.1 By Type - Global Recombinant Therapeutic Antibodies and Proteins Revenue, 2017-2022

4.2.2 By Type - Global Recombinant Therapeutic Antibodies and Proteins Revenue, 2023-2028

4.2.3 By Type - Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Recombinant Therapeutic Antibodies and Proteins Market Size, 2021 & 2028

5.1.2 Oncology

5.1.3 Hematology

5.1.4 Immunology

5.1.5 Endocrinology

5.1.6 Infectious Disease

5.1.7 Cardiovascular Disease

5.1.8 Others

5.2 By Application - Global Recombinant Therapeutic Antibodies and Proteins Revenue

& Forecasts

5.2.1 By Application - Global Recombinant Therapeutic Antibodies and Proteins Revenue, 2017-2022

5.2.2 By Application - Global Recombinant Therapeutic Antibodies and Proteins Revenue, 2023-2028

5.2.3 By Application - Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Recombinant Therapeutic Antibodies and Proteins Market Size, 2021 & 2028

6.2 By Region - Global Recombinant Therapeutic Antibodies and Proteins Revenue & Forecasts

6.2.1 By Region - Global Recombinant Therapeutic Antibodies and Proteins Revenue, 2017-2022

6.2.2 By Region - Global Recombinant Therapeutic Antibodies and Proteins Revenue, 2023-2028

6.2.3 By Region - Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Recombinant Therapeutic Antibodies and Proteins Revenue, 2017-2028

6.3.2 US Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.3.3 Canada Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.3.4 Mexico Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Recombinant Therapeutic Antibodies and Proteins Revenue, 2017-2028

6.4.2 Germany Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.4.3 France Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.4.4 U.K. Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.4.5 Italy Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.4.6 Russia Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.4.7 Nordic Countries Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.4.8 Benelux Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Recombinant Therapeutic Antibodies and Proteins Revenue, 2017-2028

6.5.2 China Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.5.3 Japan Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.5.4 South Korea Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.5.5 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.5.6 India Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Recombinant Therapeutic Antibodies and Proteins Revenue, 2017-2028

6.6.2 Brazil Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.6.3 Argentina Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Revenue, 2017-2028

6.7.2 Turkey Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.7.3 Israel Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.7.4 Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

6.7.5 UAE Recombinant Therapeutic Antibodies and Proteins Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Abbott

7.1.1 Abbott Corporate Summary

7.1.2 Abbott Business Overview

7.1.3 Abbott Recombinant Therapeutic Antibodies and Proteins Major Product

Offerings

7.1.4 Abbott Recombinant Therapeutic Antibodies and Proteins Revenue in Global Market (2017-2022)

7.1.5 Abbott Key News

7.2 Amgen

7.2.1 Amgen Corporate Summary

7.2.2 Amgen Business Overview

7.2.3 Amgen Recombinant Therapeutic Antibodies and Proteins Major Product

Offerings

7.2.4 Amgen Recombinant Therapeutic Antibodies and Proteins Revenue in Global Market (2017-2022)

7.2.5 Amgen Key News

7.3 Biogen

7.3.1 Biogen Corporate Summary

7.3.2 Biogen Business Overview

7.3.3 Biogen Recombinant Therapeutic Antibodies and Proteins Major Product

Offerings

7.3.4 Biogen Recombinant Therapeutic Antibodies and Proteins Revenue in Global Market (2017-2022)

7.3.5 Biogen Key News

7.4 Eli Lilly

7.4.1 Eli Lilly Corporate Summary

7.4.2 Eli Lilly Business Overview

7.4.3 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Major Product

Offerings

7.4.4 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Revenue in Global Market (2017-2022)

7.4.5 Eli Lilly Key News

7.5 Roche

7.5.1 Roche Corporate Summary

7.5.2 Roche Business Overview

7.5.3 Roche Recombinant Therapeutic Antibodies and Proteins Major Product

Offerings

7.5.4 Roche Recombinant Therapeutic Antibodies and Proteins Revenue in Global Market (2017-2022)

7.5.5 Roche Key News

7.6 Johnson and Johnson

7.6.1 Johnson and Johnson Corporate Summary

7.6.2 Johnson and Johnson Business Overview

7.6.3 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Major Product Offerings

7.6.4 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Revenue in Global Market (2017-2022)

7.6.5 Johnson and Johnson Key News

7.7 Merck

7.7.1 Merck Corporate Summary

7.7.2 Merck Business Overview

7.7.3 Merck Recombinant Therapeutic Antibodies and Proteins Major Product Offerings

7.7.4 Merck Recombinant Therapeutic Antibodies and Proteins Revenue in Global Market (2017-2022)

7.7.5 Merck Key News

7.8 Novo Nordisk

7.8.1 Novo Nordisk Corporate Summary

7.8.2 Novo Nordisk Business Overview

7.8.3 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Major Product Offerings

7.8.4 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Revenue in Global Market (2017-2022)

7.8.5 Novo Nordisk Key News

7.9 Pfizer

7.9.1 Pfizer Corporate Summary

7.9.2 Pfizer Business Overview

7.9.3 Pfizer Recombinant Therapeutic Antibodies and Proteins Major Product Offerings

7.9.4 Pfizer Recombinant Therapeutic Antibodies and Proteins Revenue in Global Market (2017-2022)

7.9.5 Pfizer Key News

7.10 Sanofi

7.10.1 Sanofi Corporate Summary

7.10.2 Sanofi Business Overview

7.10.3 Sanofi Recombinant Therapeutic Antibodies and Proteins Major Product Offerings

7.10.4 Sanofi Recombinant Therapeutic Antibodies and Proteins Revenue in Global Market (2017-2022)

7.10.5 Sanofi Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Recombinant Therapeutic Antibodies and Proteins Market Opportunities & Trends in Global Market

Table 2. Recombinant Therapeutic Antibodies and Proteins Market Drivers in Global Market

Table 3. Recombinant Therapeutic Antibodies and Proteins Market Restraints in Global Market

Table 4. Key Players of Recombinant Therapeutic Antibodies and Proteins in Global Market

Table 5. Top Recombinant Therapeutic Antibodies and Proteins Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Recombinant Therapeutic Antibodies and Proteins Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Recombinant Therapeutic Antibodies and Proteins Revenue Share by Companies, 2017-2022

Table 8. Global Companies Recombinant Therapeutic Antibodies and Proteins Product Type

Table 9. List of Global Tier 1 Recombinant Therapeutic Antibodies and Proteins Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Recombinant Therapeutic Antibodies and Proteins Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Recombinant Therapeutic Antibodies and Proteins Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Recombinant Therapeutic Antibodies and Proteins Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Recombinant Therapeutic Antibodies and Proteins Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Recombinant Therapeutic Antibodies and Proteins Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Recombinant Therapeutic Antibodies and Proteins

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Recombinant Therapeutic Antibodies and Proteins

Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Recombinant Therapeutic Antibodies and

Proteins Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Recombinant Therapeutic Antibodies and

Proteins Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Recombinant Therapeutic Antibodies and Proteins

Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Recombinant Therapeutic Antibodies and Proteins

Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Recombinant Therapeutic Antibodies and Proteins

Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Recombinant Therapeutic Antibodies and Proteins

Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Recombinant Therapeutic Antibodies and

Proteins Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Recombinant Therapeutic Antibodies and

Proteins Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Recombinant Therapeutic Antibodies and

Proteins Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Recombinant Therapeutic Antibodies and

Proteins Revenue, (US\$, Mn), 2023-2028

Table 30. Abbott Corporate Summary

Table 31. Abbott Recombinant Therapeutic Antibodies and Proteins Product Offerings

Table 32. Abbott Recombinant Therapeutic Antibodies and Proteins Revenue (US\$, Mn), (2017-2022)

Table 33. Amgen Corporate Summary

Table 34. Amgen Recombinant Therapeutic Antibodies and Proteins Product Offerings

Table 35. Amgen Recombinant Therapeutic Antibodies and Proteins Revenue (US\$, Mn), (2017-2022)

Table 36. Biogen Corporate Summary

Table 37. Biogen Recombinant Therapeutic Antibodies and Proteins Product Offerings

Table 38. Biogen Recombinant Therapeutic Antibodies and Proteins Revenue (US\$, Mn), (2017-2022)

Table 39. Eli Lilly Corporate Summary

Table 40. Eli Lilly Recombinant Therapeutic Antibodies and Proteins Product Offerings

Table 41. Eli Lilly Recombinant Therapeutic Antibodies and Proteins Revenue (US\$, Mn), (2017-2022)

Table 42. Roche Corporate Summary

Table 43. Roche Recombinant Therapeutic Antibodies and Proteins Product Offerings

Table 44. Roche Recombinant Therapeutic Antibodies and Proteins Revenue (US\$, Mn), (2017-2022)

Table 45. Johnson and Johnson Corporate Summary

Table 46. Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Product Offerings

Table 47. Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Revenue (US\$, Mn), (2017-2022)

Table 48. Merck Corporate Summary

Table 49. Merck Recombinant Therapeutic Antibodies and Proteins Product Offerings

Table 50. Merck Recombinant Therapeutic Antibodies and Proteins Revenue (US\$, Mn), (2017-2022)

Table 51. Novo Nordisk Corporate Summary

Table 52. Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Product Offerings

Table 53. Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Revenue (US\$, Mn), (2017-2022)

Table 54. Pfizer Corporate Summary

Table 55. Pfizer Recombinant Therapeutic Antibodies and Proteins Product Offerings

Table 56. Pfizer Recombinant Therapeutic Antibodies and Proteins Revenue (US\$, Mn), (2017-2022)

Table 57. Sanofi Corporate Summary

Table 58. Sanofi Recombinant Therapeutic Antibodies and Proteins Product Offerings

Table 59. Sanofi Recombinant Therapeutic Antibodies and Proteins Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Recombinant Therapeutic Antibodies and Proteins Segment by Type in 2021

Figure 2. Recombinant Therapeutic Antibodies and Proteins Segment by Application in 2021

Figure 3. Global Recombinant Therapeutic Antibodies and Proteins Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Recombinant Therapeutic Antibodies and Proteins Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Recombinant Therapeutic Antibodies and Proteins Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Recombinant Therapeutic Antibodies and Proteins Revenue in 2021

Figure 8. By Type - Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share, 2017-2028

Figure 9. By Application - Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share, 2017-2028

Figure 10. By Region - Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share, 2017-2028

Figure 11. By Country - North America Recombinant Therapeutic Antibodies and Proteins Revenue Market Share, 2017-2028

Figure 12. US Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Recombinant Therapeutic Antibodies and Proteins Revenue Market Share, 2017-2028

Figure 16. Germany Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 17. France Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn),

2017-2028

Figure 20. Russia Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Recombinant Therapeutic Antibodies and Proteins Revenue Market Share, 2017-2028

Figure 24. China Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 28. India Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Recombinant Therapeutic Antibodies and Proteins Revenue Market Share, 2017-2028

Figure 30. Brazil Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Revenue Market Share, 2017-2028

Figure 33. Turkey Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Recombinant Therapeutic Antibodies and Proteins Revenue, (US\$, Mn), 2017-2028

Figure 37. Abbott Recombinant Therapeutic Antibodies and Proteins Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Amgen Recombinant Therapeutic Antibodies and Proteins Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Biogen Recombinant Therapeutic Antibodies and Proteins Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Eli Lilly Recombinant Therapeutic Antibodies and Proteins Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Roche Recombinant Therapeutic Antibodies and Proteins Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Merck Recombinant Therapeutic Antibodies and Proteins Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Pfizer Recombinant Therapeutic Antibodies and Proteins Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Sanofi Recombinant Therapeutic Antibodies and Proteins Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Recombinant Therapeutic Antibodies and Proteins Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/RD3190E1EB02EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RD3190E1EB02EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

